Anti-MET Antibody Fails to Impress in Phase 3 NSCLC Trial

Onartuzumab (MetMab)did not improve PFS when combined with erlotinib (Tarceva) in the METLung trial.
Published Online: June 05, 2014

Adding the novel anti-MET monoclonal antibody onartuzumab (MetMab) to EGFR mutation-targeted therapy did not impact outcomes in a pivotal trial, although other findings suggested it may have been the population rather than the target at fault.

Progression-free survival came out nearly identical for the drug added to erlotinib (Tarceva) as with erlotinib alone (median 2.7 versus 2.6 months, P=0.92), David R. Spigel, MD, of the Sarah Cannon Research Institute in Nashville, Tenn., and colleagues found in the METLung trial.

Overall survival actually trended in favor of erlotinib alone (9.1 months versus 6.8 on the combination, P=0.07), the group reported here at the American Society of Clinical Oncology meeting.

Read the report here:
Source: Medpage Today

Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Neutropenia Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST